fldm - FLDM STOCK NEWS

Fluidigm Corporation (Nasdaq: FLDM) announced participation in the Cantor Virtual Global Healthcare Conference, where management will provide updates on business strategy and financial performance. The formal presentation, led by President and CEO Chris Linthwaite, is scheduled for September 16, 2020, at 4:00 pm ET. A live webcast will be accessible, with a replay available for 90 days. Fluidigm focuses on translational and clinical research, utilizing proprietary technologies to enhance health insights and accelerate therapy development.

Fluidigm Corporation (Nasdaq: FLDM) has received Emergency Use Authorization (EUA) from the FDA for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay, a non-invasive saliva-based test for COVID-19. This assay demonstrates 100% agreement with authorized nasopharyngeal tests and can process up to 6,000 tests daily on the Biomark™ HD platform. The test aims to improve testing access during the pandemic, with strong demand leading to new purchases of Biomark systems. Additionally, Fluidigm is collaborating with the NIH RADx program to enhance testing capacity with a proposed budget of $37 million.

Fluidigm Corporation (Nasdaq: FLDM) has entered into a distribution agreement with De Novo Software™ to provide its customers with access to the FCS Express™ 7 Flow software, enhancing data analysis for high-parameter mass cytometry. New purchases of Fluidigm's Helios™ mass cytometer and Hyperion™ Imaging System will now include a one-year license for this software, which streamlines data analysis and reporting. This agreement aims to deliver valuable insights for research in various fields, aligning with Fluidigm's commitment to improving health through advanced technology.

Fluidigm Corporation (Nasdaq: FLDM) has announced that Gnome Diagnostics is employing its microfluidics technology to enhance COVID-19 testing in Central Ohio. The newly developed Rapid Turnaround Real-Time RT-PCR™ test has been submitted for Emergency Use Authorization (EUA) by the FDA and aims to meet the increasing demand for COVID-19 testing among critical populations. Fluidigm's Biomark™ HD platform supports high-throughput testing, processing up to 6,000 tests per day while reducing reagent costs. The collaboration underscores the company's commitment to advancing testing capabilities amidst the pandemic.

Fluidigm Corporation (Nasdaq: FLDM) plans to release its second quarter 2020 financial results on August 6, 2020, after market closure. The company will host a conference call at 2:00 PM PT to discuss the results and operational updates. Interested parties can participate via a dedicated phone number or a live webcast available on Fluidigm's Investor Relations page. A press release detailing the results will precede the call, and the replay will be accessible for a limited time after the event.

Fluidigm Corporation (Nasdaq: FLDM) announced the use of its mass cytometry technology in a COVID-19 study involving up to 2,000 hospitalized adults across ten U.S. medical institutions, sponsored by the NIH. The study aims to understand immune responses related to COVID-19 severity, potentially guiding treatment strategies. Fluidigm's technology will help analyze samples collected over a year, addressing the pandemic's challenges and understanding patient journeys. The company has also filed for Emergency Use Authorization for a saliva-based COVID-19 test.

Fluidigm Corporation (Nasdaq: FLDM) has been selected by Spanish health authorities to enhance SARS-CoV-2 testing. Integrated Genetics Lab Services (iGLS) will utilize Fluidigm's microfluidics technology on the Biomark™ HD system, aiming to increase testing capacity to 6,000 tests daily. This initiative is supported by a grant from the Valencian government and began screening in early June. The technology offers significant throughput and cost advantages, making it suitable for large-scale testing, which is crucial as the need for effective COVID-19 testing persists in Spain.

Fluidigm Corporation (Nasdaq: FLDM) has filed for Emergency Use Authorization (EUA) from the FDA for a breakthrough extraction-free saliva-based test for SARS-CoV-2. Developed with Washington University School of Medicine, this test enhances testing capacity by processing up to 6,000 samples a day on the Biomark™ HD platform, which eliminates the need for invasive nasopharyngeal swabs. This innovation aims to improve testing accessibility, especially in critical populations, while addressing supply chain challenges in COVID-19 testing.

Fluidigm Corporation (Nasdaq: FLDM) announced key presentations by CEO Chris Linthwaite and CFO Vikram Jog at upcoming investor conferences. They will provide updates on the company’s business strategy and financial performance.

The presentations are scheduled for the UBS Virtual Global Healthcare Conference on May 19, 2020, at 4:40 PM ET, and the Jefferies Virtual Healthcare Conference on June 3, 2020, at 3:00 PM ET. Live webcasts will be available on the company’s investor website and archived for 30 days post-event.